Evidence map›Paper›PMID 38795231›Full record

ReviewCurrent heart failure reports2024

Estimated Glomerular Filtration Rate Slope as an Endpoint in Cardiovascular Trials.

Arsalan Hamid, Stephen J Greene, Ankit Mehta, Javed Butler, Muhammad Shahzeb Khan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current heart failure reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Arsalan HamidDepartment of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
Stephen J GreeneDuke Clinical Research Institute, Durham, NC, USA.
Ankit MehtaDivision of Nephrology, Department of Internal Medicine, Baylor University Medical Center, Dallas, TX, USA.
Javed ButlerDepartment of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.
Muhammad Shahzeb KhanDivision of Cardiology, Duke University School of Medicine, Durham, NC, USA. shahzebkhan@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewEnd stage kidney disease can be a slow process and it may be challenging to achieve required follow-up for sufficient events. Therefore, a surrogate kidney endpoint, such as estimated glomerular filtration rate (eGFR) slope maybe attractive to assess the kidney in cardiovascular trials, especially heart failure (HF). RECENT

findingseGFR slope can generate informative results in a shorter follow-up period, has decreased risk of type-2 error, and is less sensitive to eGFR shifts compared with other surrogate kidney endpoints (eGFR decline≥40% or doubling creatinine). However, eGFR slope has its limitations with acute effects, heterogeneity in slope calculation/reporting, and deviations from linearity. eGFR slope is a kidney endpoint which may be well-suited for HF trials. Cross-collaborated guideline recommendations are needed to optimize the use of eGFR slope as a kidney endpoint in patients with HF.

Indexed as

Clinical Trials as TopicGlomerular Filtration RateHeart FailureBiomarkersCardiovascular DiseasesDisease ProgressionEndpoint DeterminationHumansKidney Failure, ChronicBiomarkersDeclineEstimated Glomerular Filtration RateKidneyOutcomeRenalSurrogate Renal Endpoint

Identifiers

PMID38795231

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.